Login
$ALEC
$2.53 -$0.01 (0.39%) Live

$ALEC 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzhei...

16 Oct 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Alector, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule I hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC and BTIG, LLC are acting as representatives...

14 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 13, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Alector, Inc. (“Alector” or the “Company”) approved an option repricing. The repricing generally applied to stock options to purchase shares of the commo...

05 Oct 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

06 Aug 2026 8-K: Results of Operations and Financial Condition

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD).

08 Jul 2026 8-K: Termination of a Material Definitive Agreement

Alector, Inc. (the “Company”) was developing the investigational progranulin-elevating monoclonal antibodies, latozinemab and nivisnebart, in collaboration with Glaxo Wellcome UK Limited (“GSK”), under the Collaboration and License Agree...

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Alector, Inc. (“Alector”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, Alector’s stockholders voted on three proposals, each of which is described in more detail in the def...

07 May 2026 8-K: Entry into a Material Definitive Agreement

Alector, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows:

07 May 2026 8-K: Results of Operations and Financial Condition

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (A...

25 Feb 2026 8-K: Results of Operations and Financial Condition

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer’s Disease), AL050 ...

12 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

SOUTH SAN FRANCISCO, Calif., December 12, 2025 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that N...

06 Nov 2025 8-K: Results of Operations and Financial Condition

Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing...

21 Oct 2025 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +2 more

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

07 Aug 2025 8-K: Results of Operations and Financial Condition

On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments

13 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

— Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D.,

08 May 2025 8-K: Results of Operations and Financial Condition

Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025

28 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

On March 25, 2025, Dr. Gary Romano gave notice of his decision to resign from his position as Chief Medical Officer of Alector, Inc. (the “Company”) in order to pursue other opportunities. His resignation will be effective on April 25, 2...

10 Mar 2025 8-K: Costs Associated with Exit or Disposal Activities

On March 7, 2025, Alector, Inc. (“Alector” or “the Company”) committed to a plan to reduce its workforce (the “Plan”) by approximately 13% as part of its cost reduction initiatives in order to align resources with the Company’s strategic...

26 Feb 2025 8-K: Results of Operations and Financial Condition

Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025

10 Jan 2025 8-K: Other Events

Alector, Inc. (the “Company”) was developing AL002, its TREM2 program asset, to treat patients with early Alzheimer’s disease (AD) in collaboration with AbbVie Biotechnology, Ltd. (“AbbVie”) under the Co-Development and Option Agreement,...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support